tbuckley/cabot-search huggingface dataset:
Comments on “Endoscopic sleeve gastroplasty, laparoscopic sleeve gastrectomy, and laparoscopic greater curve plication: do they differ at 2 years?”
Authors: Abishek Katakwar, Sundeep Lakhtakia, Rupjyoti Talukdar
Journal: Endoscopy (2021)

See also: Reply to Katakwar et al.Endoscopy 2021; 53(03): 340-340DOI: 10.1055/a-1337-2500 See also: Endoscopic sleeve gastroplasty, laparoscopic sleeve gastrectomy, and laparoscopic greater curve plication: do they differ at 2 years?Endoscopy 2021; 53(03): 235-243DOI: 10.1055/a-1224-7231
Serodiagnostics for SARS-CoV-2
Authors: Mariko Harada Sassa, Kouji H. Harada
Journal: Annals of Internal Medicine (2021)

LettersFebruary 2021Serodiagnostics for SARS-CoV-2FREEMariko Harada Sassa, MD, PhD, Kouji H. Harada, PhD, MPHMariko Harada Sassa, MD, PhDKyoto University, Kyoto, JapanSearch for more papers by this author, Kouji H. Harada, PhD, MPHKyoto University, Kyoto, JapanSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L20-1395 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In their narrative review, Cheng and colleagues (1) state, “[I]f testing asymptomatic individuals when the true seroprevalence of a population is only 5%, an assay with a specificity of 95% would produce a false-positive rate of 50%.” However, their definition of false-positive rate is unclear. Is it defined as 1 − specificity (that is, 5%) or, as it is sometimes referred to, as (false positives)/(total positives)? Even if the authors used the latter definition, the sensitivity should be given for this calculation. We calculated a positive predictive value of 50% and negative predictive value of 99.7% with the assumption of sensitivity at 95%. We recommend that the authors review the calculation and definition of these values.Reference1. Cheng MP, Yansouni CP, Basta NE, et al. Serodiagnostics for severe acute respiratory syndrome–related coronavirus 2: a narrative review. Ann Intern Med. 2020;173:450-60. doi:10.7326/M20-2854 LinkGoogle Scholar Comments 0 Comments Sign In to Submit A Comment Author, Article, and Disclosure InformationAuthors: Mariko Harada Sassa, MD, PhD; Kouji H. Harada, PhD, MPHAffiliations: Kyoto University, Kyoto, JapanDisclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L20-1395. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSerodiagnostics for Severe Acute Respiratory Syndrome–Related Coronavirus 2 Matthew P. Cheng , Cedric P. Yansouni , Nicole E. Basta , Michaël Desjardins , Sanjat Kanjilal , Katryn Paquette , Chelsea Caya , Makeda Semret , Caroline Quach , Michael Libman , Laura Mazzola , Jilian A. Sacks , Sabine Dittrich , and Jesse Papenburg Serodiagnostics for SARS-CoV-2 Jesse Papenburg , Cedric P. Yansouni , Chelsea Caya, , Matthew P. Cheng Metrics February 2021Volume 174, Issue 2 Page: 287 Keywords Conflicts of interest COVID-19 Disclosure Negative predictive value Positive predictive value Specificity ePublished: 16 February 2021 Issue Published: February 2021 Copyright & PermissionsCopyright © 2021 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
<i>KRAS</i> G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma
Authors: Gregory D. Jones, Raul Caso, Kay See Tan, Brooke Mastrogiacomo, Francisco Sanchez-Vega, Yuan Liu, James G. Connolly, Yonina R. Murciano-Goroff, Matthew J. Bott, Prasad S. Adusumilli, Daniela Molena, Gaetano Rocco, Valerie W. Rusch, Smita Sihag, Sandra Misale, Rona Yaeger, Alexander Drilon, Kathryn C. Arbour, Gregory J. Riely, Neal Rosen, Piro Lito, Haiying Zhang, David C. Lyden, Charles M. Rudin, David R. Jones, Bob T. Li, James M. Isbell
Journal: Clinical Cancer Research (2021)

Abstract Purpose: KRAS G12C is the most common KRAS mutation in primary lung adenocarcinoma. Phase I clinical trials have demonstrated encouraging clinical activity of KRASG12C inhibitors in the metastatic setting. We investigated disease-free survival (DFS) and tumor genomic features in patients with surgically resected KRASG12C-mutant lung adenocarcinoma. Experimental Design: Patients who underwent resection of stage I–III lung adenocarcinoma and next-generation sequencing (NGS) were evaluated. Exclusion criteria were receipt of induction therapy, incomplete resection, and low-quality NGS. Mutations were classified as KRAS wild-type (KRASwt), G12C (KRASG12C), or non-G12C (KRASother). DFS was compared between groups using the log-rank test; factors associated with DFS were assessed using Cox regression. Mutual exclusivity and cooccurrence, tumor clonality, and mutational signatures were assessed. Results: In total, 604 patients were included: 374 KRASwt (62%), 95 KRASG12C (16%), and 135 KRASother (22%). Three-year DFS was not different between KRAS-mutant and KRASwt tumors. However, 3-year DFS was worse in patients with KRASG12C than KRASother tumors (log-rank P = 0.029). KRASG12C tumors had more lymphovascular invasion (51% vs. 37%; P = 0.032) and higher tumor mutation burden [median (interquartile range), 7.0 (5.3–10.8) vs. 6.1 (3.5–9.7); P = 0.021], compared with KRASother tumors. KRASG12C mutation was independently associated with worse DFS on multivariable analysis. Our DFS findings were externally validated in an independent The Cancer Genome Atlas cohort. Conclusions: KRAS G12C mutations are associated with worse DFS after complete resection of stage I–III lung adenocarcinoma. These tumors harbor more aggressive clinicopathologic and genomic features than other KRAS-mutant tumors. We identified a high-risk group for whom KRASG12C inhibitors may be investigated to improve survival.
Nt-probnp and Outcomes in Patients With and Without Heart Failure Hospitalized With Severe Covid-19 Pneumonia
Authors: J. Yoo, P. Grewal, A. Papamanoli, A. Mojahedi, J. Nakamura, J. Fung, J. Abata, S. Dhaliwal, R. Jacob, J. Hotelling, N. Karkala, S. T. Tsui, S. Rawal, A. Coritsidis, L. Marcos, M. Bloom, H. Skopicki, A. P. Kalogeropoulos
Journal: Circulation (2020)
Abstract PS6-39: A novel prognostic nomogram for 2-year survival in HER2-positive patients
Authors: Li Zhu, Mengdi Chen, Jiayi Wu
Journal: Cancer Research (2021)

Abstract Background: Targeted therapies have largely improved prognosis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Yet, disease can still progress rapidly for some patients in the first two years after diagnosis. Our study aimed to establish a nomogram model to predict 2-year breast cancer-specific survival (BCSS) in early HER2-positive breast cancer patients. Patients and Methods: A total of 32,481 HER2-positive patients derived from Surveillance, Epidemiology, and End Results (SEER) database were included in the construction of nomogram. Concordance index (C-index) and calibration curve were used to evaluate the discrimination ability and predictive accuracy. We also tested the model in 804 patients from Shanghai Jiao Tong University Breast Cancer Data Base (SJTU-BCDB).Results: Age, estrogen receptor (ER) status, progesterone receptor (PR) status, histologic type, T stage and N stage were selected to construct the nomogram according to multivariable analysis. The 2-year BCSS rate was 95% and 60% for patients at low risk (&amp;lt;8 points) and high risk (&amp;gt;13 scores) respectively. The C-index of model derived from SEER database is 0.81 (95%CI 0.79-0.83). Sensitivity analysis was performed in patients undergoing breast surgeries with the C-index of 0.81 (95%CI 0.79-0.83). Validation in 804 patients from SJTU-BCDB showed respective C-index of 0.77 (95%CI, 0.62-0.92) in total population, 0.67 (95%CI 0.44-0.90) in patients receiving anti-HER2 therapy and 0.90 (95%CI 0.81-0.90) in those without targeted therapy.Conclusions: The novel nomogram can predict 2-year survival outcome in HER2-positive patients independent of receiving anti-HER2 therapy or not and help clinicians to adjust therapeutic strategies for those patients with higher risk. Citation Format: Li Zhu, Mengdi Chen, Jiayi Wu. A novel prognostic nomogram for 2-year survival in HER2-positive patients [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS6-39.
Blood Pressure Effects of Sodium Reduction
Authors: Tommaso Filippini, Marcella Malavolti, Paul K. Whelton, Androniki Naska, Nicola Orsini, Marco Vinceti
Journal: Circulation (2021)

The relationship between dietary sodium intake and blood pressure (BP) has been tested in clinical trials and nonexperimental human studies, indicating a direct association. The exact shape of the dose-response relationship has been difficult to assess in clinical trials because of the lack of random-effects dose-response statistical models that can include 2-arm comparisons.After performing a comprehensive literature search for experimental studies that investigated the BP effects of changes in dietary sodium intake, we conducted a dose-response meta-analysis using the new 1-stage cubic spline mixed-effects model. We included trials with at least 4 weeks of follow-up; 24-hour urinary sodium excretion measurements; sodium manipulation through dietary change or supplementation, or both; and measurements of systolic and diastolic BP at the beginning and end of treatment.We identified 85 eligible trials with sodium intake ranging from 0.4 to 7.6 g/d and follow-up from 4 weeks to 36 months. The trials were conducted in participants with hypertension (n=65), without hypertension (n=11), or a combination (n=9). Overall, the pooled data were compatible with an approximately linear relationship between achieved sodium intake and mean systolic as well as diastolic BP, with no indication of a flattening of the curve at either the lowest or highest levels of sodium exposure. Results were similar for participants with or without hypertension, but the former group showed a steeper decrease in BP after sodium reduction. Intervention duration (≥12 weeks versus 4 to 11 weeks), type of study design (parallel or crossover), use of antihypertensive medication, and participants' sex had little influence on the BP effects of sodium reduction. Additional analyses based on the BP effect of difference in sodium exposure between study arms at the end of the trial confirmed the results on the basis of achieved sodium intake.In this dose-response analysis of sodium reduction in clinical trials, we identified an approximately linear relationship between sodium intake and reduction in both systolic and diastolic BP across the entire range of dietary sodium exposure. Although this occurred independently of baseline BP, the effect of sodium reduction on level of BP was more pronounced in participants with a higher BP level.
Abstract 14380: Inpatient Heart Failure Initiative With Home Health Outpatient Collaboration Reduces Heart Failure Readmissions
Authors: Tarun Sharma, Aaron Gopal, Deborah Crew, Stephanie Dunlap
Journal: Circulation (2019)

Introduction: Prevalence of heart failure (HF) is estimated at 5.7 million in US. HF is one of the most common inpatient diagnoses, and cost of HF care is compounded by 23.5% national readmission r...
Annals Graphic Medicine - Dr. Mom: Things I Took for Granted Prepandemic
Authors: Grace E. Farris
Journal: Annals of Internal Medicine (2021)

Web ExclusivesMarch 2021Annals Graphic Medicine - Dr. Mom: Things I Took for Granted PrepandemicFREEGrace E. Farris, MDGrace E. Farris, MDUniversity of Texas, Austin, Texas (G.E.F.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/G21-0011 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Download figure Download PowerPoint Comments0 CommentsSign In to Submit A Comment Barbara SoysterUniversity of Michigan23 February 2021 In person discussion Zoom is so helpful. But it's not the same as gathering in the same room to discuss a good book. When one person's comment leads to another...and another...and the excitement and tempo build as we realize how the book impacted each of us. But the torrent of ideas and impressions is slower and more stilted on Zoom. I'm grateful to have Zoom. But it's not the same. Can't wait for warmer weather to meet on our back porches again. Nonetheless, A Woman is No Man by Etaf Rum and The Warmth of Other Suns by Isabel Wilkerson were wonderful reads that elicited deep discussion and reflections. Author, Article, and Disclosure InformationAffiliations: University of Texas, Austin, Texas (G.E.F.)Disclosures: The author has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=G18-0042.Author/Illustrator Information: Grace E. Farris, MD, is an assistant professor of medicine at Dell Medical School at the University of Texas in Austin, Texas. You can view her work at her website: www.farrisgrace.com.About Dr. Mom: In Dr. Mom, physician and cartoonist Grace Farris examines work–life balance while mothering and doctoring. Dr. Mom appears monthly in Annals Graphic Medicine.This article was published at Annals.org on 23 February 2021. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics March 2021Volume 174, Issue 3Page: W30-W31 ePublished: 23 February 2021 Issue Published: March 2021 Copyright & PermissionsCopyright © 2021 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Bone SPECT/CT in the Evaluation of Painful Total Ankle Replacement
Authors: Jeroen Mertens, Tom Lootens, Johan Vercruysse, Bieke Van Den Bossche, Dieter Berwouts, Bieke Lambert, Tim Van den Wyngaert
Journal: Clinical Nuclear Medicine (2021)

Third-generation total ankle replacement (TAR) is an increasingly popular and effective treatment for end-stage osteoarthritis, yet identifying causes of failure remains challenging. We evaluated integrated bone SPECT/CT in recurrent pain after TAR by validating a standardized reporting scheme, identifying uptake patterns, and assessing diagnostic performance and impact on clinical management.A total of 24 TARs in 16 patients with persistent or recurrent pain received integrated bone SPECT/CT using diagnostic CT settings. Images were retrospectively reviewed, and a novel localization scheme was validated by assessing interrater agreement. Distinct uptake patterns were identified, and diagnostic test characteristics were estimated. Reference standard consisted of clinical follow-up, laboratory findings, and subsequent procedures, including revision surgery.Standardized scoring of bone SPECT/CT uptake was highly reproducible (intraclass correlation coefficient, 0.79; 95% confidence interval [CI], 0.75-0.82). The final diagnoses were gutter impingement (n = 12), periprosthetic (stress) fracture (n = 5), loosening (n = 5), tarsal arthritis (n = 1), and erysipelas (n = 1). Overall, the diagnostic test characteristics of bone SPECT/CT were as follows: sensitivity of 100% (95% CI, 82%-100%), specificity of 80% (95% CI, 28%-99%), and accuracy of 96% (95% CI, 79%-100%). Gutter impingement, periprosthetic fracture, and loosening were correctly identified in all cases revealing distinct uptake patterns. Importantly, persistent diffuse uptake was frequently observed, warranting cautious interpretation. Bone SPECT/CT impacted clinical management in 86%, with symptomatic improvement in 83% of patients.Integrated bone SPECT/CT of painful TARs may benefit from standardized localization to reveal distinct uptake patterns representing common complications after TAR. Initial results show highly promising diagnostic value with potentially important impact on clinical management.
Correspondence on ‘Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis’
Authors: Piero Ruscitti, Giorgio Sesti, Paola Cipriani, Roberto Gerli, Roberto Giacomelli
Journal: Annals of the Rheumatic Diseases (2021)

We read with interest the article by Baker et al evaluating possible associations between the rheumatoid inflammatory process and the incidence of diabetes.1 In this work, many cytokines were significantly associated with the risk of diabetes, but only interleukin (IL)-1α and IL-6 were independent predictors.1 Due to the specific study design, the authors did not differentiate between type 1 diabetes (T1D) and type 2 diabetes (T2D), although the prevalence of T1D is expected to be very low, considering the mean age of involved patients.1 However, despite this limitation, these findings are of considerable interest since they furtherly reinforce the idea of a possible pathogenic loop between the rheumatoid inflammatory process and the glucose derangement, making more difficult the management of both diseases.2

In the study by Baker et al , IL-1α strongly predicted the occurrence of diabetes.1 A growing body of evidence suggests the role of IL-1 family in pathogenesis of T2D, inducing to β-cell apoptosis.2–4 Thus, IL-1 inhibition may be considered a new therapeutic strategy in improving glucose abnormalities, although conflicting results are available in the literature.5–9 A recent large …
Public policy and health in the Trump era
Authors: Steffie Woolhandler, David U Himmelstein, Sameer Ahmed, Zinzi Bailey, Mary T Bassett, Michael Bird, Jacob Bor, David Bor, Olveen Carrasquillo, Merlin Chowkwanyun, Samuel L Dickman, Samantha Fisher, Adam Gaffney, Sandro Galea, Richard N Gottfried, Kevin Grumbach, Gordon Guyatt, Helena Hansen, Philip J Landrigan, Michael Lighty, Martin McKee, Danny McCormick, Alecia McGregor, Reza Mirza, Juliana E Morris, Joia S Mukherjee, Marion Nestle, Linda Prine, Altaf Saadi, Davida Schiff, Martin Shapiro, Lello Tesema, Atheendar Venkataramani
Journal: The Lancet (2021)
Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study
Authors: Lourdes M. Perez-Chada, Rebecca H. Haberman, Vinod Chandran, Cheryl F. Rosen, Christopher Ritchlin, Lihi Eder, Philip Mease, Soumya Reddy, Alexis Ogdie, Joseph F. Merola, Jose U. Scher
Journal: Nature Reviews Rheumatology (2021)

Abstract The concept of psoriatic arthritis (PsA) prevention is gaining increased interest owing to the physical limitation, poor quality of life and low remission rates that are achieved with current therapies for PsA. The psoriasis-to-PsA transition offers a unique opportunity to identify individuals at increased risk of developing PsA and to implement preventive strategies. However, identifying individuals at increased risk of developing PsA is challenging as there is no consensus on how this population should be defined. This Consensus Statement puts forward recommended terminology from the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) for defining specific subgroups of individuals during the preclinical and early clinical phases of PsA to be used in research studies. Following a three-round Delphi process, consensus was reached for three terms and definitions: ‘increased risk for PsA’, ‘psoriasis with asymptomatic synovio-entheseal imaging abnormalities’ and ‘psoriasis with musculoskeletal symptoms not explained by other diagnosis’. These terms and their definitions will enable improved identification and standardization of study populations in clinical research. In the future, as increasing evidence emerges regarding the molecular and clinical features of the psoriasis-to-PsA continuum, these terms and definitions will be further refined and updated.
Correction to: Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer
Authors: Senlin Zhao, Yushuai Mi, Bingjie Guan, Binbin Zheng, Ping Wei, Yanzi Gu, Zhengxiang Zhang, Sanjun Cai, Ye Xu, Xinxiang Li, Xuefeng He, Xinyang Zhong, Guichao Li, Zhiyu Chen, Dawei Li
Journal: Journal of Hematology & Oncology (2021)

An amendment to this paper has been published and can be accessed via the original article.
Abstract 14823: Comparison of a Novel Computed Tomography-Based Assessment of Mitral Annular Calcification to Transthoracic Echocardiogram
Authors: Jakob Park, Angela Y Higgins, Yekaterina Kim, Bradley Kay, Kamil Faridi, Robert L McNamara, Vratika Agarwal, HAMID MOJIBIAN, Lissa Sugeng, David Hur
Journal: Circulation (2020)

Introduction: Mitral annular calcification (MAC) is associated with increased stroke and death. The typical assessment by transthoracic echocardiography (TTE) is qualitative visual rating (VR), but this technique is user-dependent and lacks a gold standard for grading. Computed tomography (CT) has high sensitivity for calcium and can quantify MAC. The purpose of this study is to standardize grading of MAC and compare TTE-based assessment of MAC with CT. Methods: The analysis included 60 patients with non-contrast CT and TTE prior to aortic valve replacement or mitral valve (MV) repair. MAC was assessed on TTE by VR (none, mild, moderate, severe), a previously described echo calcium score (ECS), and systematic MAC grading (SMAC). TTE-based MV parameters were recorded. CT data were measured for calcium volume (MACV) via proprietary software (Visage Imaging) by an independent rater with 3D regions of interest in the MV area. Results: Mean age was 77 ± 11; 42% of patients were female. MACV for tertile-based groups (lowest, middle, highest) are shown in the Table. CT detected MAC in a notable portion of patients without MAC by TTE-derived methods: in 16 of 29 patients (55%) by VR, in 5 out of 15 (33%) by ECS, and in 5 out of 16 (31%) by SMAC. Fifteen of 22 patients (68%) with mild MAC by VR had middle or high-tertile MAC on CT. MACV-derived categories reclassified 65%, 60%, and 54% of patients compared with VR, ECS, and SMAC grading by TTE, respectively. Differences were also found across MACV categories for MV velocity, transmitral gradient, and E/e’. Except E/e’, trends were independent of TTE-based MAC analysis and significant after adjusting for mitral regurgitation or stenosis. Conclusions: TTE has limited ability to detect mild MAC compared with CT. This novel CT-based volumetric MAC assessment is feasible and can improve standardized quantification and sensitivity to detect MAC at lower values. Higher MACV by CT was associated with increasingly abnormal MV flow and diastology.